Oncology Institute Earnings Call Signals Profitable Shift

Oncology Institute, Inc. ((TOI)) has held its Q4 earnings call. Read on for the main highlights of the call.

Oncology Institute, Inc. struck an upbeat tone on its latest earnings call, pointing to record revenue, its first positive adjusted EBITDA quarter, and a stronger balance sheet as evidence that its model is scaling. Management acknowledged seasonal and transitional headwinds, but framed them as manageable against clear momentum heading into its 2026 profitability and growth targets.

Record Revenue and Strong Top-Line Growth

Oncology Institute crossed a major milestone in 2025, posting full year revenue of $502.7 million, up about 27.8 percent from $393.4 million a year earlier. Fourth quarter revenue surged 41.6 percent to $142.0 million from $100.3 million, underscoring accelerating growth as the company exited the year.

Material Pharmacy and Dispensing Expansion

Pharmacy and dispensing operations remained the key growth engine, with full year pharmacy revenue climbing 49.6 percent to $269.2 million. In the fourth quarter, pharmacy contributed 57.4 percent of total revenue at $81.4 million, up 71.1 percent year over year, while pharmacy gross profit jumped 84.7 percent to $14.9 million and margins improved to 18.3 percent.

First Positive Adjusted EBITDA as a Public Company

The company delivered an important profitability milestone with fourth quarter 2025 adjusted EBITDA turning slightly positive at $147,000, compared with a loss of $7.8 million in the prior year period. Management reiterated its expectation for full year positive adjusted EBITDA in 2026 and guided to a range of zero to $9 million, suggesting continued operating improvement.

Improving Gross Profitability Across the Business

Gross profit in the fourth quarter grew to $22.7 million from $14.6 million a year earlier, with overall gross margin expanding to 16.0 percent from 14.6 percent. Patient services were a notable contributor, as gross profit in that segment rose 59.5 percent to $7.1 million and margins increased to 11.9 percent from 8.9 percent.

Capitation and Delegated Model Drive High-Value Growth

Oncology Institute deepened its value-based care model by adding nine new capitated contracts in 2025, covering roughly 260,000 additional lives and lifting capitation revenue 17.2 percent to $80.5 million. The delegated model in Florida was particularly impactful, generating over $10 million in new capitated revenue in 2025 and exiting the year with an annualized run rate near $50 million despite delegated members representing under 5 percent of capitated lives.

Operating Leverage and SG&A Cost Discipline

The company continued to show operating leverage, as SG&A expense excluding depreciation and amortization fell to 19.7 percent of revenue in the quarter from 24.8 percent a year prior, a decline of more than 500 basis points. Management expects SG&A to trend toward roughly 16 percent of revenue in 2026, supported in part by about $2 million of savings from AI driven efficiency initiatives.

Stronger Balance Sheet and Early Cash Generation

Oncology Institute exited the year with $33.6 million in cash and reduced the balance on its convertible preferred note by $24 million, lowering leverage risk. Fourth quarter operating cash flow was a positive $3.2 million and free cash flow turned positive, though the company still envisions a path where sustained free cash flow generation is not expected until the end of 2026.

Strategic Partnerships and Leadership Initiatives

Management highlighted new payer partnerships, including an expansion with Elevance and new arrangements with Humana and CarePlus that add about 22,000 Medicare Advantage lives in South Florida. The company is also preparing to launch a proprietary network portal in the second quarter of 2026, scaling outsourced clinical trials operations, and strengthening its leadership team and board to support the next phase of growth.

Seasonal Weakness and Expected Q1 Loss

Despite the strong finish to 2025, executives cautioned that the first quarter is typically the weakest, as patient deductibles reset and reimbursement lags. For the first quarter of 2026, adjusted EBITDA is expected to be a loss of $3 million to $1 million, particularly given that the prior year quarter benefited from a one time $1.6 million item.

Pharmacy Concentration Risk and Drug Pricing Exposure

The company’s success in pharmacy also creates concentration risk, as pharmacy and dispensing represented 57.4 percent of fourth quarter revenue and about $269 million for the full year. Management acknowledged that changes in drug pricing or reimbursement could significantly affect results, even though it currently expects only a minor impact from recent policy changes for specific drugs.

Fee-for-Service Growth Moderation and Cannibalization

Fee for service revenue grew a modest 9 percent year over year to $148.5 million in 2025, lagging other segments. Leadership noted that as capitated lives increase, some fee for service volume may be cannibalized, and they now expect this line to be flat to grow only in the low single digits in 2026 as value based arrangements expand.

Delegated Ramp and Medical Loss Ratio Pressure

The build out of delegated contracts presents a short term drag on margins, with management warning of somewhat higher medical loss ratios during ramp periods. Over time, delegated arrangements are expected to target around an 85 percent medical loss ratio, compared with lower levels in narrow network contracts, suggesting a trade off between growth and near term profitability.

Free Cash Flow Uncertainty and Ongoing Investments

The free cash flow outlook for 2026 remains wide, with guidance ranging from negative $15 million to positive $5 million, reflecting uncertainty and continued investment needs. While SG&A has improved meaningfully, the company anticipates only modest further percentage reductions in 2026 as it continues to fund growth initiatives, limiting the pace of near term margin expansion.

Guidance and Forward-Looking Outlook

Oncology Institute reaffirmed its January 2026 outlook, projecting revenue between $630 million and $650 million, up sharply from 2025 with roughly $150 million of capitated revenue and more than 80 percent growth in that segment. The company expects gross profit of $97 million to $107 million with 100 to 200 basis points of margin expansion, adjusted EBITDA of zero to $9 million, SG&A near 16 percent of revenue, and free cash flow improving toward breakeven to modestly positive by year end.

On balance, the earnings call painted a picture of a company moving beyond proof of concept toward scaled profitability, even as it manages concentration and execution risks. Investors will be watching pharmacy trends, delegated contract performance, and cash flow closely, but the combination of rapid top line growth, rising margins, and reaffirmed 2026 targets underpinned a decidedly constructive tone.